Welcome to our dedicated page for Gyre Therapeutics SEC filings (Ticker: GYRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech reports rarely read like light bedtime material, and Gyre Therapeutics鈥� SEC filings are no exception. Each 10-K spans hundreds of pages covering Hydronidone trial data, cash runway projections and cross-border regulatory hurdles鈥攄etails critical to anyone tracking anti-fibrotic therapies or MASH-related liver fibrosis. If you have ever searched for 鈥淕yre Therapeutics SEC filings explained simply鈥� or wondered how to decode a sudden 8-K on trial enrollment pauses, you know the challenge.
Stock Titan solves that problem. Our AI-powered summaries turn dense disclosures into clear insights, spotlighting R&D spend, FDA correspondence and segment risks in seconds. Looking for 鈥淕yre Therapeutics quarterly earnings report 10-Q filing鈥� to gauge burn rate? Need real-time alerts on 鈥淕yre Therapeutics insider trading Form 4 transactions鈥� before the market reacts? We stream every document straight from EDGAR and layer it with concise context, so you can focus on decisions, not page counts.
Explore every filing type in one place:
- 10-K: 鈥淕yre Therapeutics annual report 10-K simplified鈥� pinpoints pipeline timelines and financing outlook.
- 10-Q: 鈥淕yre Therapeutics earnings report filing analysis鈥� tracks quarter-over-quarter R&D spend.
- 8-K: 鈥淕yre Therapeutics 8-K material events explained鈥� flags trial milestones or partnership updates.
- Form 4: 鈥淕yre Therapeutics Form 4 insider transactions real-time鈥� highlights executive buys and sells.
- DEF 14A: 鈥淕yre Therapeutics proxy statement executive compensation鈥� reveals incentive alignment.
Whether you鈥檙e understanding Gyre Therapeutics SEC documents with AI or monitoring 鈥淕yre Therapeutics executive stock transactions Form 4,鈥� our platform keeps you ahead with instant access, expert context and AI-driven clarity.
Gyre Therapeutics (GYRE) reported consolidated revenue of $26.8 million for the quarter and $48.8 million for the six months ended June 30, 2025, driven by Gyre Pharmaceuticals product sales. Net income was $1.58 million for the quarter and $5.31 million for six months; net income attributable to common stockholders was $0.44 million for the quarter and $3.14 million for six months. Cash and cash equivalents increased to $36.5 million on June 30, 2025, aided by a May 2025 underwritten offering that raised $23.0 million gross (net proceeds ~$21.3 million) and ATM proceeds of $0.5 million.
The company launched two products in 2025鈥擟ontiva (commercialization began March 2025) and Etorel (commercialization began June 2025); Etorel technology rights were recorded at ~$4.9 million. Total assets were $152.6 million and total equity $129.4 million. Management states existing liquidity and access to capital are expected to fund operations for at least 12 months. Key risks disclosed include heavy customer concentration (Sinopharm ~52% of revenue/accounts receivable), PRC cross-border restrictions and an accumulated deficit of $70.3 million.
Gyre Therapeutics reported a leadership transition and furnished a press release with its quarterly results. Ping Zhang was appointed Interim Chief Executive Officer effective August 5, 2025, succeeding Han Ying, Ph.D., who resigned as CEO and as a director to become the companys Senior Vice President, Science. Mr. Zhang has served as a company director since January 2025 and as Executive Chair since March 2025, and his background includes senior roles in private equity, venture capital and corporate leadership in China and Japan.
In connection with the interim CEO appointment, Mr. Zhang received a grant of 250,000 stock options, with 25% vesting on August 5, 2026 and the remainder vesting in equal monthly installments over the following three years, subject to continued service. The company furnished a press release as Exhibit 99.1 announcing financial results for the three and six months ended June 30, 2025, and listed the interactive data cover page as Exhibit 104.
Gyre Therapeutics director Zhang Ping received a stock option grant to purchase 250,000 shares of the company's common stock with an exercise price of $6.92. The transaction date is 08/05/2025. The option vests 25% on 08/05/2026 and the remainder vests in equal monthly installments over the following three years, contingent on continued service. The option has an expiration date of 08/05/2035 and the reporting form shows 250,000 derivative securities beneficially owned following the grant, held directly.
FAQ
What is the current stock price of Gyre Therapeutics (GYRE)?
What is the market cap of Gyre Therapeutics (GYRE)?
